Rebecca Kusko
Pre-Doctoral Trainee
Boston University School of Medicine, Division of Graduate Medical Sciences
Dept of Genetics & Genomics



Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Brothers JF, Ung M, Escalante-Chong R, Ross J, Zhang J, Cha Y, Lysaght A, Funt J, Kusko R. Integrity, standards, and QC-related issues with big data in pre-clinical drug discovery. Biochem Pharmacol. 2018 Mar 15; 152:84-93. PMID: 29551586.
     
  2. Shi L, Kusko R, Wolfinger RD, Haibe-Kains B, Fischer M, Sansone SA, Mason CE, Furlanello C, Jones WD, Ning B, Tong W. The international MAQC Society launches to enhance reproducibility of high-throughput technologies. Nat Biotechnol. 2017 Dec 08; 35(12):1127-1128. PMID: 29220036.
     
  3. Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight. 2017 Dec 07; 2(23). PMID: 29212949.
     
  4. Ross CJ, Towfic F, Shankar J, Laifenfeld D, Thoma M, Davis M, Weiner B, Kusko R, Zeskind B, Knappertz V, Grossman I, Hayden MR. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Med. 2017 May 31; 9(1):50. PMID: 28569182.
     
  5. Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018 01; 175(2):168-180. PMID: 28369768; DOI: 10.1111/bph.13798;.
     
  6. Towfic F, Kusko R, Zeskind B. Letter to the Editor response: Nygaard et al. Biostatistics. 2017 Apr 01; 18(2):197-199. PMID: 27780809; DOI: 10.1093/biostatistics/kxw031;.
     
  7. Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. Cancer Cell. 2016 Dec 12; 30(6):940-952. PMID: 27960087; DOI: 10.1016/j.ccell.2016.11.006;.
     
  8. Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, Bezprozvanny I. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis. 2017 Jan; 97(Pt A):46-59. PMID: 27818324; DOI: 10.1016/j.nbd.2016.10.006;.
     
  9. Kusko RL, Brothers JF, Tedrow J, Pandit K, Huleihel L, Perdomo C, Liu G, Juan-Guardela B, Kass D, Zhang S, Lenburg M, Martinez F, Quackenbush J, Sciurba F, Limper A, Geraci M, Yang I, Schwartz DA, Beane J, Spira A, Kaminski N. Integrated Genomics Reveals Convergent Transcriptomic Networks Underlying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016 Oct 15; 194(8):948-960.View Related Profiles. PMID: 27104832.
     
  10. Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR. Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Hum Mol Genet. 2016 Sep 15; 25(18):3975-3987. PMID: 27466197; DOI: 10.1093/hmg/ddw238;.
     
Showing 10 of 13 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 13 publications over 6 distinct years, with a maximum of 5 publications in 2017

YearPublications
20121
20131
20141
20164
20175
20181
Contact for Mentoring:


75 E. Newton St Evans Building
Boston MA 02118
Google Map


Kusko's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department